Drug profile · INN
reslizumab
CINQAERO
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
reslizumab (CINQAERO) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN reslizumab
Brand CINQAERO
Route INJECTION
Formulation INJECTABLE
ATC code R03DX08
Originator Teva Pharma GmbH
Frequently asked questions
What is reslizumab?
reslizumab (CINQAERO) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for reslizumab?
CINQAERO is a marketed brand name for reslizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of reslizumab?
reslizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.